ABEL acc. to WHO [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2018-05-21 14:47 (882 d 12:07 ago) – Posting: # 18794
Views: 1,700

Hi Kotu,

» […] Acceptance off Bio equivalence studies conducted in Replicate study design by ANVISA (Brazil).

Replicate designs – although for average bioequivalence – are acceptable for the ANVISA for ages (even mentioned in the guidance).

» […] what is the acceptance criteria to be followed (USFDA/Europe Approach).

If you mean reference-scaling, the latter (actually the WHO’s). See this post. Confirmed by a Brazilian colleague earlier this month.

Dif-tor heh smusma 🖖
Helmut Schütz

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

 Admin contact
21,162 posts in 4,410 threads, 1,476 registered users;
online 2 (0 registered, 2 guests [including 2 identified bots]).
Forum time: Tuesday 02:54 UTC (Europe/Vienna)

In theory, there is no difference between theory and practice.
But, in practice, there is.    Jan L.A. van de Snepscheut

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz